Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Xilio Therapeutics Inc’s stock clocked out at $1.01, down -8.18% from its previous closing price of $1.10. In other words, the price has decreased by -$8.18 from its previous closing price. On the day, 0.75 million shares were traded. XLO stock price reached its highest trading level at $1.1 during the session, while it also had its lowest trading level at $0.954.
Ratios:
To gain a deeper understanding of XLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.67 and its Current Ratio is at 1.67. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on December 21, 2022, initiated with a Buy rating and assigned the stock a target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.
On November 16, 2021, Raymond James started tracking the stock assigning a Outperform rating and target price of $31.Raymond James initiated its Outperform rating on November 16, 2021, with a $31 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’25 when Frankenfield Christopher James sold 6,954 shares for $0.98 per share. The transaction valued at 6,841 led to the insider holds 12,421 shares of the business.
Brennan Kevin M. sold 1,803 shares of XLO for $1,774 on Jan 02 ’25. The SVP, FINANCE AND ACCOUNTING now owns 3,197 shares after completing the transaction at $0.98 per share. On Dec 18 ’24, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,759,978 shares for $1.04 each. As a result, the insider paid 1,830,377 and bolstered with 9,105,451 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 46175280 and an Enterprise Value of -8446345. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.27 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at -1.828 whereas that against EBITDA is 0.135.
Stock Price History:
Over the past 52 weeks, XLO has reached a high of $1.93, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -3.85%, while the 200-Day Moving Average is calculated to be 2.48%.
Shares Statistics:
It appears that XLO traded 481.40K shares on average per day over the past three months and 1686590 shares per day over the past ten days. A total of 43.96M shares are outstanding, with a floating share count of 18.77M. Insiders hold about 57.29% of the company’s shares, while institutions hold 16.09% stake in the company. Shares short for XLO as of 1734048000 were 119440 with a Short Ratio of 0.25, compared to 1731628800 on 41958. Therefore, it implies a Short% of Shares Outstanding of 119440 and a Short% of Float of 0.33000002.
